|
1
|
Zaharie F, Muresan MS, Petrushev B, Berce
C, Gafencu GA, Selicean S, Jurj A, Cojocneanu-Petric R, Lisencu CI,
Pop LA, et al: Exosome-carried microRNA-375 inhibits cell
progression and dissemination via Bcl-2 blocking in colon cancer. J
Gastrointestin Liver Dis. 24:435–443. 2015.PubMed/NCBI
|
|
2
|
Takeyama H, Yamamoto H, Yamashita S, Wu X,
Takahashi H, Nishimura J, Haraguchi N, Miyake Y, Suzuki R, Murata
K, et al: Decreased miR-340 expression in bone marrow is associated
with liver metastasis of colorectal cancer. Mol Cancer Ther.
13:976–985. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Konno Y, Dong P, Xiong Y, Suzuki F, Lu J,
Cai M, Watari H, Mitamura T, Hosaka M, Hanley SJ, et al:
MicroRNA-101 targets EZH2, MCL-1 and FOS to suppress proliferation,
invasion and stem cell-like phenotype of aggressive endometrial
cancer cells. Oncotarget. 5:6049–6062. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Achberger S, Aldrich W, Tubbs R, Crabb JW,
Singh AD and Triozzi PL: Circulating immune cell and microRNA in
patients with uveal melanoma developing metastatic disease. Mol
Immunol. 58:182–186. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Okada H, Kohanbash G and Lotze MT:
MicroRNAs in immune regulation-opportunities for cancer
immunotherapy. Int J Biochem Cell Biol. 42:1256–1261. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hazama S, Nakamura Y, Takenouchi H, Suzuki
N, Tsunedomi R, Inoue Y, Tokuhisa Y, Iizuka N, Yoshino S, Takeda K,
et al: A phase I study of combination vaccine treatment of five
therapeutic epitope-peptides for metastatic colorectal cancer;
safety, immunological response, and clinical outcome. J Transl Med.
12:632014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Suzuki N, Hazama S, Ueno T, Matsui H,
Shindo Y, Iida M, Yoshimura K, Yoshino S, Takeda K and Oka M: A
phase I clinical trial of vaccination with KIF20A-derived peptide
in combination with gemcitabine for patients with advanced
pancreatic cancer. J Immunother. 37:36–42. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
U.S Department of Health and Human
Services FaDA, . October;2011.U.S. Department of Health and Human
Services, Food and Drug Administration, October 2011: Guidance for
Industry. Clinical Considerations for Therapeutic Cancer Vaccines.
2011.
|
|
9
|
Nagorsen D and Thiel E: Clinical and
immunologic responses to active specific cancer vaccines in human
colorectal cancer. Clin Cancer Res. 12:3064–3069. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Copier J, Whelan M and Dalgleish A:
Biomarkers for the development of cancer vaccines: Current status.
Mol Diagn Ther. 10:337–343. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Whiteside TL: Immune responses to cancer:
Are they potential biomarkers of prognosis? Front Oncol. 3:1072013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yagyu R, Furukawa Y, Lin YM, Shimokawa T,
Yamamura T and Nakamura Y: A novel oncoprotein RNF43 functions in
an autocrine manner in colorectal cancer. Int J Oncol.
25:1343–1348. 2004.PubMed/NCBI
|
|
13
|
Shimokawa T, Matsushima S, Tsunoda T,
Tahara H, Nakamura Y and Furukawa Y: Identification of TOMM34,
which shows elevated expression in the majority of human colon
cancers, as a novel drug target. Int J Oncol. 29:381–386.
2006.PubMed/NCBI
|
|
14
|
Kikuchi T, Daigo Y, Katagiri T, Tsunoda T,
Okada K, Kakiuchi S, Zembutsu H, Furukawa Y, Kawamura M, Kobayashi
K, et al: Expression profiles of non-small cell lung cancers on
cDNA microarrays: Identification of genes for prediction of
lymph-node metastasis and sensitivity to anti-cancer drugs.
Oncogene. 22:2192–2205. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Olofsson B, Korpelainen E, Pepper MS,
Mandriota SJ, Aase K, Kumar V, Gunji Y, Jeltsch MM, Shibuya M,
Alitalo K and Eriksson U: Vascular endothelial growth factor B
(VEGF-B) binds to VEGF receptor-1 and regulates plasminogen
activator activity in endothelial cells. Proc Natl Acad Sci USA.
95:pp. 11709–11714. 1998; View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Millauer B, Wizigmann-Voos S, Schnurch H,
Martinez R, Møller NP, Risau W and Ullrich A: High affinity VEGF
binding and developmental expression suggest Flk-1 as a major
regulator of vasculogenesis and angiogenesis. Cell. 72:835–846.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hazama S, Nakamura Y, Tanaka H, Hirakawa
K, Tahara K, Shimizu R, Ozasa H, Etoh R, Sugiura F, Okuno K, et al:
A phase II study of five peptides combination with
oxaliplatin-based chemotherapy as a first-line therapy for advanced
colorectal cancer (FXV study). J Transl Med. 12:1082014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Uchida N, Tsunoda T, Wada S, Furukawa Y,
Nakamura Y and Tahara H: Ring finger protein 43 as a new target for
cancer immunotherapy. Clin Cancer Res. 10:8577–8586. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Suda T, Tsunoda T, Daigo Y, Nakamura Y and
Tahara H: Identification of human leukocyte antigen-A24-restricted
epitope peptides derived from gene products upregulated in lung and
esophageal cancers as novel targets for immunotherapy. Cancer Sci.
98:1803–1808. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ishizaki H, Tsunoda T, Wada S, Yamauchi M,
Shibuya M and Tahara H: Inhibition of tumor growth with
antiangiogenic cancer vaccine using epitope peptides derived from
human vascular endothelial growth factor receptor 1. Clin Cancer
Res. 12:5841–5849. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wada S, Tsunoda T, Baba T, Primus FJ,
Kuwano H, Shibuya M and Tahara H: Rationale for antiangiogenic
cancer therapy with vaccination using epitope peptides derived from
human vascular endothelial growth factor receptor 2. Cancer Res.
65:4939–4946. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Iizuka N, Oka M, Yamada-Okabe H, Nishida
M, Maeda Y, Mori N, Takao T, Tamesa T, Tangoku A, Tabuchi H, et al:
Oligonucleotide microarray for prediction of early intrahepatic
recurrence of hepatocellular carcinoma after curative resection.
Lancet. 361:923–929. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Boon T and van der Bruggen P: Human tumor
antigens recognized by T lymphocytes. J Exp Med. 183:725–729. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Okabe H, Satoh S, Kato T, Kitahara O,
Yanagawa R, Yamaoka Y, Tsunoda T, Furukawa Y and Nakamura Y:
Genome-wide analysis of gene expression in human hepatocellular
carcinomas using cDNA microarray: Identification of genes involved
in viral carcinogenesis and tumor progression. Cancer Res.
61:2129–2137. 2001.PubMed/NCBI
|
|
25
|
Okuno K, Sugiura F, Itoh K, Yoshida K,
Tsunoda T and Nakamura Y: Recent advances in active specific cancer
vaccine treatment for colorectal cancer. Curr Pharm Biotechnol.
13:1439–1445. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kijima T, Hazama S, Tsunedomi R, Tanaka H,
Takenouchi H, Kanekiyo S, Inoue Y, Nakashima M, Iida M, Sakamoto K,
et al: Micro RNA-6826 and −6875 in plasma are valuable non-invasive
biomarkers that predict the efficacy of vaccine treatment against
metastatic colorectal cancer. Oncol Rep. 37:23–30. 2017.PubMed/NCBI
|
|
27
|
Li X, Shi Y, Yin Z, Xue X and Zhou B: An
eight-miRNA signature as a potential biomarker for predicting
survival in lung adenocarcinoma. J Transl Med. 12:1592014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lu YC, Chang JT, Liao CT, Kang CJ, Huang
SF, Chen IH, Huang CC, Huang YC, Chen WH, Tsai CY, et al:
OncomiR-196 promotes an invasive phenotype in oral cancer through
the NME4-JNK-TIMP1-MMP signaling pathway. Mol Cancer. 13:2182014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ge J, Chen Z, Li R, Lu T and Xiao G:
Upregulation of microRNA-196a and microRNA-196b cooperatively
correlate with aggressive progression and unfavorable prognosis in
patients with colorectal cancer. Cancer Cell Int. 14:1282014.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pan Y, Meng M, Zhang G, Han H and Zhou Q:
Oncogenic microRNAs in the genesis of leukemia and lymphoma. Curr
Pharm Des. 20:5260–5267. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen WX, Ren LH and Shi RH: Implication of
miRNAs for inflammatory bowel disease treatment: Systematic review.
World J Gastrointest Pathophysiol. 5:63–70. 2014.PubMed/NCBI
|
|
32
|
Galon J, Mlecnik B, Bindea G, Angell HK,
Berger A, Lagorce C, Lugli A, Zlobec I, Hartmann A, Bifulco C, et
al: Towards the introduction of the ‘Immunoscore’ in the
classification of malignant tumours. J Pathol. 232:199–209. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang GJ, Zhou H, Xiao HX, Li Y and Zhou
T: MiR-378 is an independent prognostic factor and inhibits cell
growth and invasion in colorectal cancer. BMC Cancer. 14:1092014.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lee DY, Deng Z, Wang CH and Yang BB:
MicroRNA-378 promotes cell survival, tumor growth and angiogenesis
by targeting SuFu and Fus-1 expression. Proc Natl Acad Sci USA.
104:pp. 20350–20355. 2007; View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chen H, Ren C, Han C, Wang D, Chen Y and
Fu D: Expression and prognostic value of miR-486-5p in patients
with gastric adenocarcinoma. PLoS One. 10:e01193842015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang J, Tian X, Han R, Zhang X, Wang X,
Shen H, Xue L, Liu Y, Yan X, Shen J, et al: Downregulation of
miR-486-5p contributes to tumor progression and metastasis by
targeting protumorigenic ARHGAP5 in lung cancer. Oncogene.
33:1181–1189. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Song L, Lin C, Gong H, Wang C, Liu L, Wu
J, Tao S, Hu B, Cheng SY, Li M and Li J: miR-486 sustains NF-κB
activity by disrupting multiple NF-κB-negative feedback loops. Cell
Res. 23:274–289. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Fisher DT, Appenheimer MM and Evans SS:
The two faces of IL-6 in the tumor microenvironment. Semin Immunol.
26:38–47. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Gajewski TF, Schreiber H and Fu YX: Innate
and adaptive immune cells in the tumor microenvironment. Nat
Immunol. 14:1014–1022. 2013. View Article : Google Scholar : PubMed/NCBI
|
